Home › Myasthenia Gravis › New York
Myasthenia Gravis clinical trials in New York
12 studies for Myasthenia Gravis are looking for participants at sites in New York.
Cities in New York
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1036, New York
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Nov 13, 2026 · NCT07039916A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Mg0038 10106, Amherst
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07463521ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Dent Neurologic Institute - Amherst, Amherst
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07673627Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Equity Medical, New York
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Nov 3, 2026 · NCT07217587A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, New York
- TG Therapeutics Investigational Trial Site, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06680037ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Dent Neurologic Institute - Amherst, Amherst
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07294170Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases
- Columbia University Irving Medical Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06626919RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Columbia University, New York
- University of Rochester Medical Center, Rochester
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Oct 19, 2026 · NCT06359041Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
- Columbia University Irving Medical Center, New York
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Oct 19, 2026 · NCT07304154ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Dent Neurologic Institute - Amherst, Amherst
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07284420Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, New Hyde Park
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 18, 2026 · NCT04202341The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
- Neurological Associates of Long Island, P.C., Lake Success
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Apr 11, 2025 · NCT05564936From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.